Hyundai Pharm (004310.KS) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · South Korea · ISIN KR7004310009
Hyundai Pharm financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 175.74 bn KRW | 191.79 bn KRW |
| Gross profit | 73.37 bn KRW | 79.60 bn KRW |
| Operating income | 180.89 m KRW | 4.16 bn KRW |
| EBIT | 253.65 m KRW | 4.19 bn KRW |
| Net income | -574.89 m KRW | 2.52 bn KRW |
| Diluted EPS – continuing operations | -22.00 KRW | 81.39 KRW |
Full history since 1999, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Hyundai Pharm
Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical devices in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, antitussives, cell stimulants and proliferants, central nervous system, depilatory, dermatological agent, dermatology, dietary supplements, digestive system, endocrine system, expectorants, eye tonic and vitamins, gynaecolog antifungals, gynaecologic antiseptics, hemostatics, labour inhibitors, leukotriene modulator, narcotic analgesics, NSAIDs, oestrogens, ophthalmic products, OTH.sex horm and similar, SERMS, systemic hormonal contraceptives, urogenital system depilatory, uterotonic products, various alimentary tract and metabolism products, vitamins, acne, allergy, alopecia treatment, analgesics and anti-inflammatory, anemia, antimicrobial and antivirus, arthritis, contraceptives, dermatological agent, diagnostic reagent, gastrointestinal disorder and digestant, lip care, nutrition, ophthalmic product, respiratory, urogenital system, wound healing, and others. Hyundai Pharmaceutical Co., Ltd. was founded in 1965 and is headquartered in Seoul, South Korea.
More stocks
- enGene Therapeutics Inc. (ENGN)
- MKH Oil Palm (East Kalimantan) Berhad (5319.KL)
- Westag (WUG.F)
- Shanghai Material Trading Co Ltd B (900927.SS)
- King Core Electronics Inc (6155.TW)
- MainStreet Bancshares, Inc. (MNSB)
- Hoyne Bancorp, Inc. (HYNE)
- Hemisphere Energy Corporation (HME.V)
- Saraswanti Anugerah Makmur Pt (SAMF.JK)
- Frontier Energy Ltd (FHE.AX)
- Western Investment Company of Canada Limited (WI.V)
- Well Chip Group Berhad (5325.KL)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.